InterCure Reports Stellar Revenue Growth and Strategic Plans

InterCure's Remarkable Financial Performance

InterCure Ltd. (NASDAQ: INCR), a leading player in the global cannabis industry, has reported an impressive NIS 130 million in revenue for the first half of 2025. This achievement marks a 15% increase from the second half of 2024 and a 3% rise compared to the same period the previous year. The company also demonstrated resilience by generating NIS 12 million in positive operating cash flow, marking its eleventh consecutive half of positive Adjusted EBITDA.

CEO Alexander Rabinovitch's Insights

Alexander Rabinovitch, the CEO of InterCure, expressed confidence in the company’s performance despite ongoing challenges. "Our ability to continue generating solid revenue and positive cash flow amid difficulties reinforces the strength of our business model. We are optimistic about our growth trajectory and our expansion into international markets, notably with the strategic acquisition of ISHI," he stated.

Financial Highlights in Detail

During this reporting period, InterCure achieved significant financial milestones:

• Revenue: NIS 130 million
• Adjusted EBITDA: NIS 12.6 million, constituting 10% of revenue
• Net Loss: NIS 1.8 million, compared to nearly break-even in H1 2024
• Cash Flow: Improved from negative NIS 43 million last year to positive NIS 12 million
• Cash Reserves: Increased to NIS 54 million

Operational Adjustments and New Ventures

As recovery processes continue, InterCure has resumed operations at its Nir Oz facility, producing cannabis products once again. The company launched over 40 new SKUs, marking a significant product introduction amid market recovery.

Strategic Acquisition and Future Prospects

A pivotal moment in InterCure's journey is its agreement to acquire Botanico Ltd. (ISHI). This move is set to enhance the company's access to premium U.S. genetics and advanced cultivation technologies, expanding its footprint in the cannabis market.

InterCure's management is actively monitoring regulatory changes in the U.S., particularly regarding cannabis rescheduling, which could further bolster its market positioning. Rabinovitch emphasized, "By leveraging the acquisition of ISHI and adjusting to market dynamics, we are confident in capitalizing on new opportunities in the expanding cannabis industry."

About InterCure

InterCure, operating under the brand Canndoc, is recognized as Israel's largest licensed cannabis producer, boasting a high-margin seed-to-sale model. The company not only leads the market in Israel but is also rapidly expanding its presence globally. InterCure is dedicated to providing pharmaceutical-grade products, underpinned by rigorous manufacturing standards.

For investors and stakeholders looking for comprehensive financial insights, they are encouraged to review the company's annual reports and updates available on their SEC filings. The continuous growth and strategic maneuvers by InterCure showcase its commitment to strengthening its position in the global cannabis sector.

Frequently Asked Questions

What were InterCure's revenue figures for the first half of 2025?

InterCure reported revenues of NIS 130 million for the first half of 2025.

How does the current financial performance compare to previous periods?

The revenue represents a 15% increase from the last half of 2024 and a 3% increase compared to the same period in 2024.

What strategic acquisition is InterCure involved in?

InterCure is in the process of acquiring Botanico Ltd. (ISHI), which will strengthen its access to U.S. cannabis genetics and technologies.

How did InterCure's operating cash flow change?

InterCure generated a positive cash flow of NIS 12 million, a significant improvement from a negative cash flow of NIS 43 million in the previous year.

What is InterCure's market outlook?

InterCure is optimistic about future growth, particularly with its ongoing international expansion and the dynamic changes in the cannabis regulatory landscape.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.